Report overview
Irritable bowel syndrome (IBS) is a common disorder that affects the large intestine. Signs and symptoms include cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both. IBS is a chronic condition that need to manage long term.
IBS that causes increased diarrhea is often called IBS-D. Diarrhea predominant irritable bowel syndrome (IBS-D) is a subtype of IBS in which a person experiences frequent episodes of diarrhea with accompanying abdominal pain. Like IBS, IBS-D is a functional gastrointestinal disorder (FGD) in that there is no visible disease, inflammation, or injury to account for its symptoms. It is estimated that approximately a third of people who have IBS experience the disorder with diarrhea as the predominant bowel habit.
In this report, we study the drugs for diarrhea predominant irritable bowel syndrome (IBS-D).
This report aims to provide a comprehensive presentation of the global market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs. This report contains market size and forecasts of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in global, including the following market information:
Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs companies in 2022 (%)
The global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market was valued at US$ 1428.3 million in 2022 and is projected to reach US$ 2826.1 million by 2029, at a CAGR of 10.2% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North America is the largest consumption place of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, followed by Europe. The two account for more than 80% of the consumer market in together. The most used IBS-D drug is XIFAXAN, accounting for more than 60% of the market share, followed by Viberzi and Lotronex. IBS-D drugs are widely sold through hospital pharmacies and retail pharmacies.
We surveyed the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Segment Percentages, by Type, 2022 (%)
XIFAXAN
Viberzi
Lotronex
Other
Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market, by Sales Channel, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Segment Percentages, by Sales Channel, 2022 (%)
Hospitals Pharmacy
Retail Pharmacy
Other
Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs revenues share in global market, 2022 (%)
Key companies Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bausch Health
Allergan
Sebela Pharmaceuticals
Astellas Pharmaceuticals
Amneal Pharms
Pharscin Pharma
Outline of Major Chapters:
Chapter 1: Introduces the definition of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, market overview.
Chapter 2: Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by sales channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
